





























Paraphrasing the famous quote “Nothing in Biology 
Makes Sense Except in the Light of Evolution”, one can 
say that nothing in aging makes sense except in the light 
of TOR-driven quasi-programmed aging, a continuation 
of developmental growth driven by growth-promoting 
pathways. And life span extension by mild damage 
makes no sense, if aging is a decline caused by 
accumulation of damage. 
  
Conventional view on aging 
It is believed that aging is a decline, deterioration due to 
accumulation of random molecular and cellular damage 
caused by free radicals, radiation, stresses, pathogens, 
toxins, carcinogens, mistakes in replication/translation, 
protein misfolding and even mechanical forces. If aging 
is caused by damage, then damaging stresses would 
accelerate aging (Figure 1A). However, mild stresses 
(including oxidative stress) can extend life span in 
different species [1-30]. 
 
How this can be reconciled with the conventional theory 

































First, hormesis is an artefact. Certainly there are many 
artefacts in this field. Yet, there are also solid data 
especially on the life-extension by calorie restriction, 
ROS, heat shock and phytochemicals.  
 
Second, the phenomenon of hormesis rules out the 
conventional theory of aging. Furthermore, as it was 
already reviewed, “damage-induced aging” theory was 
ruled out by other evidence too [31-38]. It was 
discussed that aging is not the life-long accumulation of 
molecular damage, is not decline and is not caused by 
reactive oxygen species (ROS) [35].  
 
Third, instead of rejecting the damage-induced theory, 
paradoxical assumptions were suggested to reconcile it 
with hormesis (Figure 1B). To explain extension of 
lifespan by mild and repeated stresses, it was suggested 
that (a) mild stresses stimulate maintenance and repair 
pathways and (b) cause adaptation of cells and the 
ability to tolerate stronger stresses. Let us briefly review 
the attempt to reconcile hormesis and molecular 
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Conventional explanations of hormesis 
Heat shock 
Repeated exposure to mild heat shock increases life 
span in Drosophila [11]. It was suggested that mild heat 
shock reduces damage and protein aggregation by 
activating internal antioxidant, repair and degradation 
processes [2, 3]. In other words, chronic cellular stress 
may prolong life span by either activating repair 
mechanisms or by causing cell adaptation or both [1-3].  
 
Calorie restriction  
It was suggested that calorie restriction (CR) is a low-
intensity stressor, which enhances the ability of animals 
to cope with intense stressors [4]. For example, in 
young rodents, CR causes an increase in the afternoon 
peak concentration of plasma corticosterone, a stress 
hormone [5, 39]. Another explanation is completely 
paradoxical. If damage is not completely repaired 
because resources for repair are limited by food supply, 
as suggested by Kirkwood [40], this predicts that CR 
(less resources) must accelerate aging (Figure 1A). It 
was also suggested by Kirkwood that, although the 
repair is limited by insufficient resources, the more 
resources (food), the less repair (Figure 1B). The reason 
of self-contradiction is that aging, according to the same 
theory, is purposefully regulated and the organism may 
choose to age slower [40]. The paradoxes of this point 
of view were recently discussed [34, 38, 41] and will 




























In some studies, an increased production of reactive 
oxygen species (ROS) correlated with extended life 
span in different species. To explain such paradoxical 
results it was suggested that an increased ROS in turn 
increases resistance to ROS, thus extending life span [ 
1, 12, 14]. It was suggested that ROS leads to a 
condition of mild stress, which in turn enhances vitality 
[12]. In C. elegans reduced glucose availability 
promoted formation of ROS, induces catalase activity, 
and increased oxidative stress resistance, cumulating in 
extension of life span [15].  
 
Two noticeable problems 
First, it is paradoxical to decrease damage by causing 
damage (Figure 1B).  There is no similar example in 
medicine. If one wishes to prevent stroke due to high 
blood pressure, one needs to decrease blood pressure 
not to increase it. Examples are endless including 
weight control to prevent diabetes and quitting smoking 
to prevent lung cancer. No one will advocate “mild and 
repeated” smoking to prevent lung cancer even though 
it might activate the defenses. The simple reason is that 
DNA damage is actually involved in cancer initiation. 
But even cancer-promoting damage is not random: 
mutations activate growth-promoting pathways 
including PI3K/mTOR, the most universal alteration in 
cancer  [42-45]. And cancer-initiating damage does not 
cause cellular decline (in contrast, cancer cells are very 
Figure 1. Paradoxical links between damage and aging. (A) If agings is caused by damage,
then  hormetic  damage  should  accelerate  aging.  Also  food  by  providing  resources  should
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cancer, requiring rounds of cell replication, selection 
[46, 47] and organismal aging [48]. By slowing down 
aging, CR and rapamycin delay cancer (without 
affecting mutations). The notion that aging promotes 
cancer is beyond the topic of this article and cannot be 
discussed here.  The point here is that since DNA damage 
contributes to cancer, no one will suggest hormetic 
smoking or radioactivity (at any doses) to delay cancer. 
In analogy, if damaging hormesis may delay aging, aging 
cannot be possibly be caused by damage. 
 
Second problem is the suggestion that mild hormetic 
stresses protect against severe stresses. What are these 
severe stresses? Even according to the conventional 
view, aging is not caused by accidental injures that are 
stronger than hormetic damage. It is caused by 
‘everyday’   ROS and other background stresses. Let’s 
ask a straightforward question. Are hormetic stresses 
stronger or weaker than those that cause aging? And 
there is no answer. If damage that drives aging does not 
sufficiently induce protective response, then hormesis is 
stronger than aging-causing stresses. Then why is the 
purpose of hormesis to protect from stronger stresses? 
This question will be easily answered in the light of 
TOR-driven aging.  
 
Solution: a new view on aging 
If aging is driven by damage, then damage must 
accelerate aging. If hormesis induces damage and slows 
down aging, then aging is not driven by damage. So a 
straightforward explanation is that aging is not caused 
by accumulation of molecular damage [36]. It was 






















will take the TOR-centric model for granted, which then 
will become new dogma (ironically)” [35].  
 
It is becoming evident that ROS do not cause aging and 
furthermore often is associated with longevity [26, 27, 
30, 49,  50-66]. 
 
While rejecting ROS-driven aging, scientists still do not 
dare to reject the view that aging is a decline due to 
accumulation of random damage. Yet data exclude not 
only ROS but also damage as a cause of aging. For 
example, in C elegans, CR did not decrease the 
accumulation of spontaneous mutations with age but 
nevertheless extended life span [54].  
 
Yes, perhaps, molecular damage accumulates but 
organisms do not live long enough to age from this 
accumulation. Even humans, long-living organisms, do 
not die from a decline due to such an accumulation. 
(And of course worm that lives just 5 days [67] cannot 
possibly accumulate deadly levels of molecular 
damage). Instead any human being has died from age-
related diseases, which are caused by active cellular 
processes initiated by hyper-activation of signaling 
pathways including mTOR [36, 68]. The pathogenesis 
of diseases is well known. In contrast, a mysterious 
cellular decline due to accumulation of molecular 
damage is the fiction of gerontology, unknown in 
medical science.  
 
Instead of trying to adopt the phenomenon of hormesis 
to the view on aging as accumulation of random 
























hormones  activate  the  nutrient‐sensing  TOR  (Target  of  Rapamycin)  pathway,  which  promotes
growth and then aging, causing age‐related diseases. In turn, diseases cause non‐random organ
damage and  death.  Hormesis  type  A  inhibits  TOR  thus  slowing  down  aging. Hormesis  type  B
increases aging‐tolerance and tolerance to complications of age‐related diseases. 
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The nutrient-sensing TOR pathway is activated by 
insulin, growth factors and nutrients (Figure 2).  In turn, 
it increases protein synthesis, stimulates ribosomal 
biogenesis and cell mass growth (causing cell 
hypertrophy), inhibits autophagy, induces accumulation 
of aggregation-prone proteins, increases growth factors 
(GF) secretion and causes resistance to GF and insulin 
[69-79]. 
 
  The TOR pathway drives cellular mass growth. In 
proliferating cells, cellular growth is balanced by cell 
division [80]. In quiescent (resting) cells, growth-
promoting pathways drive senescence [80, 81]. When 
the cell cycle is blocked but mTOR is still active, it 
causes hypertrophic, hyperactive, hyper-functional (for 
example, hyper-secretory) phenotype, with 
compensatory resistance to signals such as insulin and 
growth factors [82, 83] and compensatory lysosomal 
activation. In other words, mTOR converted quiescence 
into senescence, the process that was named gerogenic 
conversion or geroconversion or gerogenesis [83].  
 
In brief, TOR causes cellular hyper-functions, specific 
to each tissue such as bone resorption by osteoclasts and 
arterial wall tonus by smooth muscle cells, manifested 
as osteoporosis and hypertension, for instance. This 
eventually damages organs (aging-induced 
catastrophes). As discussed, secretory phenotype [84] or 
(more generally) hyper-functional phenotype [31] links 
cell senescence to organismal aging and specifically to 
age-related diseases. The TOR pathway is involved in 
diseases such as cancers, type II diabetes and its 
complications (retinopathy and renal hypertrophy), age-
related macular degeneration, obesity, atherosclerosis, 
cardiac hypertrophy, organ fibrosis (liver, renal and 
cardiac fibrosis), osteoporosis, Alzheimer's and 
Parkinson’s diseases and arthritis [31, 32, 38, 68, 74, 
85-89].  Organisms die from age-related diseases. TOR 
is involved in all of them [31, 68].  In other words, TOR 
limits life span by accelerating age-related diseases. In 
humans (and other mammals), age-related diseases are 
manifestations of aging that actually limit life span. 
Age-related diseases culminate in sudden catastrophes 
(Figure 2). For example, death of cardiocytes, during 
myocardial infarction, is often caused ischemia due to 
the arterial occlusion. Such occlusions result from 
increased coagulation and platelet hyper-function, 
atherosclerosis, inflammatory state and high blood 
pressure.  Age-related osteoporosis culminates in the 
broken hip, diabetes - in renal failure, hypertension - in 
stroke, just to name a few. Inhibition of the TOR 
pathway prolongs life span in yeast, worm, flies and 
mice [77, 90-107]. Genes for aging (named gerogenes 
[37]) constitute the TOR pathway [37]. Genes for 
longevity (named gerosuppressors) antagonize the TOR 
pathway [37]. Furthermore, some “anti-aging” hormetic 
agents antagonize this pathway too.  
 
Longevity: (a) slow aging and (b) aging-tolerance 
Life span can be extended by either (a) slowing down 
aging and (b) by increasing aging tolerance, defined as 
the ability to survive complications (catastrophes) of 
aging [36]. 
  
a. Obviously, inhibition of aging should extend life span 
and delay age-related diseases. For example, calorie 
restriction (CR) slows aging. CR delays age-related 
diseases such as cancer and atherosclerosis, thus 
extending life span. In other words, inhibition of 
mTOR-driven aging delays catastrophic complications 
of aging: namely, complications of age-related diseases 
such as stroke, myocardial infarction (Figure 2). These 
non-random catastrophes actually cause death.  
 
b.  But inhibition of aging (and delaying diseases) is not 
the only way to extend life span. The second way is to 
increase aging tolerance, which allows an organism to 
survive catastrophes caused by age-related diseases.  
 
Why organisms age 
The existence of aging is well understood from the 
evolutionary perspective and was discussed in detail.   
Roughly speaking, in the wild, organisms do not live 
long enough to experience aging. Therefore forces of 
natural selection against aging are weak. Only in 
protected environment (humans, domestic and 
laboratory animals) die from aging.  
 
Why organisms have low aging-tolerance 
From the evolutionary perspective, organisms do not 
tolerate aging for the same reason why they age in the 
first place. In the wild, organisms do not live long 
enough to experience aging and therefore organisms are 
not naturally shaped to experience complications of 
aging. Organisms are not selected by nature for aging-
tolerance. For example, parts of myocardium depend on 
a single coronary artery. The occlusion of a coronary 
artery causes life-threatening ischemia. Collateral 
arteries would prevent ischemia. Natural selection 
would favor such anatomical re-design, if it will extend 
reproductive life span. If humans were routinely 
reproducing after the age of 70, then variations with 
additional branches of coronary arteries would be 
selected.  
 
Thus myocardial ischemia, due to artery occlusion is 
one of the most common causes of death. The occlusion 
may result from thrombosis of atherosclerotic coronary 
arteries. But if the ischemic zone would receive blood 
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survive the catastrophe. Thus, anatomical modifications 
of a myocardial blood supply would increase aging-
tolerance without affecting aging itself. Noteworthy, 
this is how coronary stents extend lifespan without 
affecting aging. Most medical treatments increase aging 
tolerance, thus extending an average life span despite 
chronic age-related diseases.  In contrast, pharma-
cological suppression of aging would increase healthy 
lifespan by postponing diseases [108]. 
 
Two types of hormesis: (a) slowing down aging and 
(b) increasing aging-tolerance 
Hormetic stresses include two groups of agents that (a) 
slow down aging by inhibiting the TOR pathway and 
(b) increase aging tolerance, without affecting the aging 
process (Figure 2). We will call them hormesis A and 
hormesis B. Examples of hormesis A are calorie restrict-
tion, rapamycin, resveratrol and p53-inducing agents. 
Examples of hormesis B are adaptive preconditioning to 
ischemia and coronary bypass. Heat shock, hypoxia and 




Caloric restriction (CR) markedly extends life span in 
diverse species from yeast to mammals and delays the 
occurrence and/or slows progression of age-associated 
diseases [109-118]. It was suggested that CR slows 
down aging via the TOR pathway in yeast, C. elegans 
and Drosophila and mammals [34, 93, 94, 119-[122]. In 
humans, it has been shown that nutrients activate TOR 
in the muscle tissue, causing insulin-resistance, 
preventable by rapamycin [123]. Starvation or CR de-
activates the TOR pathway [71, 96, 97, 124]. Thus, by 




Plants, microorganisms and sea animals produce toxic 
agents that inhibit or damage microtubules, DNA and 
many other vital targets. Due to their toxicity, some of 
them are used as anti-cancer drugs, although nature did 
not created them for that purpose. Nature of course 
created these poisons to hurt predators and competitors 
[125, 126]. Similarly, rapamycin is an antifungal 
antibiotic produced by bacteria. TOR stimulates growth 
in response to nutrients. Therefore, soil bacteria produce 
rapamycin to inhibit yeast growth. While inhibiting 
TOR-dependent growth, rapamycin slows down TOR-
dependent aging in older yeast [93, 94]. Given that 
cancer (like aging) is “a form of growth”, the mTOR 
pathway is activated in cancer. And, although not 
created for that purpose by nature, inhibitors of mTOR 
are used as anticancer agents [42, 43, 127, 128]. I wish 
to emphasize again that bacteria produce rapamycin 
neither as a medicine for longevity nor as an anticancer 
drug, but as an antifungal antibiotic. Simply the same 
signaling pathways that are involved in growth also are 
involved in cancer and aging [88]. Growth suppressants 
may suppress aging because aging is a continuation of 
growth, driven by the same TOR/S6K pathway [129]. 
To extend lifespan, they either should inhibit the TOR 
pathway or increase aging tolerance (Figure 2). 
 
Rapamycin 
Rapamycin extends life span in yeast, drosophila and 
mice [94, 98, 99, 130, 101, 103, 130]. It is indicated for 
almost all age-related diseases [31, 48, 68, 131]. 
Rapamycin is not toxic for normal cells at 
concentrations that exceed therapeutic levels 1000 fold 
[132], [133]. There are no side effects of high dose 
rapamycin in healthy volunteers [123, 134]. Rapamycin 
has been used in children [135] and in pregnant women 
[136]. Despite common misconception that rapamycin 
is an immunosuppressant, rapamycin improves 
immunity in mice when used appropriately [137-139]. 
As an anti-aging modality, rapamycin could be used in 
doses and schedules that do not cause side effects [132]. 
 
Resveratrol  
Resveratrol, a natural agent found in grape skins, 
prevents age-related diseases and extends lifespan in 
several species [10, 140-145], including mice on high-
fat diet [144]. Resveratrol activates sirtuins [10, 146-
147], which inhibit the TOR pathway (see for 
references [148]). Resveratrol indirectly antagonizes 
the mTOR/S6K pathway upstream and downstream 
[129, 149-153], in part via activation of AMPK and 
sirtuins [154-160]. Plants produce resveratrol to 
protect grapes from parasites. But, coincidentally, 
inhibition of the TOR pathway slows down aging. 
Thus, the anti-aging effect of resveratrol may be just a 
side effect of targeting mTOR. Yet, at concentrations 
that inhibit mTOR the gerosuppressive effect of 
resveratrol is limited by its toxicity [149]. This is not 
surprising, given that resveratrol inhibits mTOR at 
micro-molar concentrations at which it also inhibits 
multiple unrelated targets. This may explain why anti-
aging effects in mice may be limited by resveratrol 
toxicity [161]. As a potential solution, resveratrol at 




The anti-diabetic drug metformin activates AMPK, 
which in turn antagonizes the mTOR pathway [24, 162-
165]. Metformin decreases insulin resistance, prevents 
diabetes and its complications, decrease incidence of 
heart diseases and cancer [166-168]. In rodents, 
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Physical exercise  
As an example of hormesis A, chronic increase in 
physical activity inhibits mTOR/S6K1 in rat skeletal 
muscle [175]. Physical activity can also increase aging-
tolerance, acting as hormesis B. 
 
Heat shock 
The TOR pathway stimulates Cap-dependent protein 
synthesis. Elevated temperature inhibits cap-dependent 
protein synthesis. Thus, heat shock blocks TOR-
stimulated protein synthesis. For example, heat shock 
protein Hsp27 inhibits translation during heat shock by 
binding eIF4G [176]. Therefore, heat shock acts as 
“hormesis A” by imitating TOR inhibition. The small 
heat-shock proteins also delay the onset of polygluta-
mine-expansion protein aggregation, suggesting that 
these proteins couple the normal aging process to this 
type of age-related disease [177]. Also, HSPs and 
chaperones can increase resistance or tolerance to 
catastrophic complications of aging, defining them also 
as hormesis B. 
 
Hypoxia  
Depending on conditions, HIF-1 and hypoxia have 
different effects on longevity [30, 65, 178].  mTOR via 
phosphorylation of S6K/S6 and 4EBP1 induce cap-
dependent translation. In contrast, hypoxia decreases 
cap-dependent translation. Hypoxia inhibits protein 
synthesis by deactivation of the mTOR pathway as well 
as by inactivation of eIF2α and eEF2 factors [179-186].  
 
p53-inducing stresses 
DNA damage induces p53, which is known to inhibit 
mTOR pathway both upstream and downstream of 
mTOR [187-197].  Induction of p53 by nutlin-3a can 
suppress senescent phenotype or suppress conversion of 
quiescence into senescence [197-200]. The gero-
suppressive effect is evident only when p53 is capable 
to inhibit mTOR [198, 201]. In certain conditions, p53 
may act as an anti-aging agent [202-207].  
 
Hormesis B 
Hormesis B extends life span by increasing aging 
tolerance. Mild stresses prepare organism to 
catastrophes caused by diseases of aging. Examples of 
catastrophes include stroke and myocardial ischemia. 
The occlusion of a cerebral artery for 60 min (injurious 
ischemia) damages the brain. The occlusion of the same 
cerebral artery for 15 min (preconditioning) protects 
from the damage caused by injurious ischemia [208]. 
Similarly, severe myocardial ischemia causes 
irreversible injury. Mild ischemia protects the heart 
from severe ischemia. Similarly, by inducing HSPs, 
heat shock may protect the myocardium from severe 
ischemia. Repeated, transient ischemic episodes or heat 
shock augment the ischemic tolerance of affected 
myocardium. Upregulation of immediate early genes 
and heat shock genes plays an important role in 
myocardial adaptation to acute ischemic stress [209]. 
Also, hormetic stresses can cause growth of collateral 
arteries. This coronary collateral function can preserve 
ischemic myocardium [210]. 
 
The cardioprotection against myocardial injury by 
regular exercise may include the development of 
collateral coronary arteries and induction of myocardial 
heat shock proteins [211]. 
 
Similarly, coronary bypass protected heart from 
ischemia. Although we do not call such medical 
procedures hormesis, there is no strict borderline 
between them and hormesis B. For example, 
reconditioning, hypoxia, and stresses may “train” 
cardiomyocutes to survive acute episode of coronary 
thrombosis. Also, it develops small blood vessels that 
could compensate for the occlusion of main artery. 
  
Now we can solve the second problem of hormesis (see 
“two noticeable problems”). The answer is: hormetic 
stresses protect from stronger stresses. But these 
stronger stresses are not those that cause aging (aging is 
not caused by any stresses). These are complications of 
aging or age-related diseases. We call them 




The hypothesis that aging is NOT driven by 
accumulation of random damage allows us to explain 
hormesis. Type A hormesis antagonizes the TOR 
pathway (Figure 2). Hormesis B causes stresses 
including damaging stresses. Since aging is not caused 
by damage, this does not contribute to aging but instead 
may cause aging-tolerance, thus protecting organisms 
from lethal consequences of aging-induced 
catastrophes.  
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